You are here

BCRF Grantee Since

2006

Donor Recognition

The Housewares Charity Foundation Award

William J. Gradishar, MD, FACP

Director, Breast Medical Oncology
Professor of Medicine
Betsy Bramsen Professor of Breast Oncology
Director, Maggie Daley Center for Women’s Cancer Care
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Current Research

Basal-like tumors, which include those classified as triple negative, are clinically aggressive and lack targeted therapies. Drs. Gradishar and Cryns and colleagues have shown that a cell stress protein called αB-crystallin contributes to the aggressive behavior of basal-like/triple-negative tumors. More recently, they developed new experimental models of basal-like breast cancer and have shown that αB-crystallin regulates the spread ("metastasis") of breast tumor cells to the brain and other organs. During the next year of BCRF funding, the researchers will use these unique models to test new therapies aimed at reducing brain and other metastases. These studies could lead to new treatments for metastatic basal-like breast cancer.

Bio

William J. Gradishar is Betsy Bramsen Professor of Breast Oncology in the Division of Hematology and Medical Oncology at the Feinberg School Medicine at Northwestern University and a member of the Robert H. Lurie Comprehensive Cancer Center. He is Director of the Maggie Daley Center for Women’s Cancer Care. He has been Chair of the Annual Lynn Sage Breast Cancer Symposium since its inception. His research focuses on the development of novel therapeutics for the treatment of breast cancer.

A Fellow of the American College of Physicians, Dr. Gradishar is also a member of the American Association for Cancer Research, the American Federation for Clinical Research, and the Association of Subspecialty Professors. He is past chair of the Oncology Training Program Committee and Communications Committee of the American Society of Clinical Oncology (ASCO). He is Chair-elect of the ASCO Professional Development Committee and a member of ASCO’s Scientific Program Committee. He is a member of the Breast Cancer Core Committee and Co-Chair of the Developmental Therapeutics Working Group of the Eastern Cooperative Oncology Group, the Committee on Cancer of the American College of Surgeons, the National Comprehensive Cancer Network (NCCN) Breast Cancer Guidelines Panel, and the NCCN Breast Cancer Prevention Panel. He also serves as a consultant to the Oncology Drug Advisory Committee of the FDA. He has served on numerous study sections and is a member of the editorial board for the Journal of Clinical Oncology, Oncology, Clinical Breast Cancer, Journal Watch, European Journal of Clinical and Medical Oncology and Clinical Cancer Research.

Co-Investigators